Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02741440 : Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
PhaseN/A
AgesMin: 12 Years Max: N/A
Eligibility
- INCLUSION CRITERIA:

To be eligible, the following inclusion criteria must be met, where applicable.

1. Participant must be 12 years of age or older.

2. Participant must be able to understand and sign the protocol s informed consent
document on their own behalf OR, in the case of a minor, have a legal guardian/parent
with the ability to do the same.

3. Participant must be able to produce a recordable electroretinogram (ERG).

4. Participant must have the ability to cooperate the required testing. Participants
unable to cooperate with one or more tests may be included only at the discretion of
the Principal Investigator.

5. Participant must be willing and able to provide a blood sample.

6. Any female participant of childbearing potential must agree to have pregnancy testing
prior to undergoing MRI.

7. Participant has molecularly-confirmed, symptomatic SCA7, as defined by CAG repeat
expansion in the ATXN7 gene of greater than 35 repeats. Accrual will be biased
towards those with lower numbers of abnormal repeats (above 35 repeats) as they are
most likely to be able to cooperate with testing. Participants who have clinical
findings consistent with SCA7 and a relative who has had molecular diagnosis, may be
included in the study with subsequent confirmation of the number of repeats. Patients
who have clinical findings consistent with SCA7 but no molecular diagnosis may be
evaluated under an NEI screening, genetics bank, or evaluation and treatment protocol
with subsequent molecular diagnosis performed within 6 months of their initial visit.

EXCLUSION CRITERIA:

A participant is not eligible if any of the following exclusion criteria are present.

1. Participant is unable to cooperate with ophthalmic/neurologic testing, including
inability to undergo brain MRI without sedation.

2. Participant has comorbidity, unrelated to ocular pathology, compromising the ability
to view/image the retina and/or record an ERG.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02741440      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740